Inventor · disambiguated record
Anke Klippel
Also filed as: KLIPPEL ANKE
6 granted patents·10 pending applications·35 citations·filing 1995–2025
81Inventor score
Top patents by PatentIndex Score
16 records- 0189US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0281US11787859B2TIM-3 antagonists for the treatment and diagnosis of cancersBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Oct 17, 2023·3 cites·16 claims
- 0379US2024389562A1Transgenic mouse expressing human cereblonCELGENE CORP·Filed 2024·Application pending·0 cites
- 0473US2024117044A1Tim-3 antagonists for the treatment and diagnosis of cancersBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 0567US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 0664US2025171538A1Tim-3 antagonists for the treatment and diagnosis of cancersBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 0763US6300111B1Constitutively active phosphatidylinositol 3-kinase and uses thereofUNIV CALIFORNIA·Filed 1999·Granted Oct 9, 2001·13 cites·8 claims
- 0862US11963520B2Transgenic mouse expressing human cereblonCELGENE CORP·Filed 2017·Granted Apr 23, 2024·0 cites·7 claims
- 0958US6043062AConstitutively active phosphatidylinositol 3-kinase and uses thereofUNIV CALIFORNIA·Filed 1995·Granted Mar 28, 2000·9 cites·15 claims
- 1054US2006228346A1Constitutively active phosphatidylinositol 3-kinase and uses thereofUNIV CALIFORNIA·Filed 2001·Application pending·0 cites
- 1154US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
- 1249US2004091898A1PI 3-kinase fusion mutants and uses thereofFiled 2003·Application pending·0 cites
- 1344US2017242014A1Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2014·Application pending·0 cites
- 1436US6613956B1PI 3-kinase fusion mutants and uses thereofCHIRON CORP·Filed 1997·Granted Sep 2, 2003·5 cites·4 claims
- 1536US2018231561A1Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
- 1636US2017038387A1Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anke Klippel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →